Zai Lab (NASDAQ:ZLAB) Posts Earnings Results, Beats Estimates By $0.07 EPS

07 May 2026, 22:50 by Amy Steele · The Cerbat Gem

Zai Lab (NASDAQ:ZLAB – Get Free Report) issued its earnings results on Thursday. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.07, Zacks reports. The business had revenue of $99.61 million for the quarter, compared to analyst estimates of $108.43 million. Zai Lab had a negative net margin of 38.15% and a negative return on equity of 22.81%.

Here are the key takeaways from Zai Lab’s conference call:

At 1.6 mg/kg, zoci showed a confirmed intracranial ORR of 62.5% (best intracranial response ~69% including 4 CRs) with ~16% grade ≥3 treatment‑related AEs; the Phase III DLLEVATE study is on track to finish enrollment H1 2027 with an interim analysis/possible accelerated approval next year and a planned first global BLA submission in late 2027.
Zai announced global collaborations with Amgen and Boehringer Ingelheim to explore zoci combined with DLL3 T‑cell engagers (and combinations with PD‑L1/chemo), with an Amgen triplet cohort already enrolling to potentially deepen and extend responses.
Q1 total product revenue fell 6% YoY to $99.6M (driven by lower ZEJULA sales and class/generic pressures) and loss from operations widened 23% to $69.4M; management expects full‑year 2026 product revenue pressure with a return to growth in 2027.
Zai ended the quarter with a strong cash position of $761.3M and a commercially profitable regional business, while planning AI‑driven efficiency measures and local XACDURO manufacturing in 2027 to ease supply constraints and improve margins.
Other pipeline moves include ZL‑1503 (IL‑13/IL‑31 bispecific) with encouraging preclinical data and expected healthy‑volunteer/AD Phase I data in H2 2026, ZL‑1311 entering clinic by year‑end, ZL‑6201 in clinic, and regional submissions for Tumor Treating Fields and TIVDAK.

Zai Lab Stock Down 5.9%

Shares of Zai Lab stock opened at $19.76 on Friday. The stock has a market capitalization of $2.24 billion, a P/E ratio of -12.27 and a beta of 0.85. The company has a 50-day simple moving average of $20.23 and a 200 day simple moving average of $20.12. Zai Lab has a 12-month low of $15.96 and a 12-month high of $44.34.

Insider Activity

In other Zai Lab news, insider Rafael Amado sold 9,910 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $20.39, for a total value of $202,064.90. Following the transaction, the insider directly owned 59,761 shares in the company, valued at $1,218,526.79. The trade was a 14.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ying Du sold 5,576 shares of the company’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $20.39, for a total transaction of $113,694.64. Following the sale, the chief executive officer directly owned 1,125,279 shares in the company, valued at $22,944,438.81. This represents a 0.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 46,187 shares of company stock worth $930,647 over the last ninety days. Corporate insiders own 4.96% of the company’s stock.

Institutional Investors Weigh In On Zai Lab

An institutional investor recently raised its position in Zai Lab stock. Royal Bank of Canada raised its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Free Report) by 214.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the quarter. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent SEC filing. 41.65% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Jefferies Financial Group raised shares of Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th. JPMorgan Chase & Co. lowered their price objective on Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. Weiss Ratings raised Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Cantor Fitzgerald dropped their target price on Zai Lab from $55.00 to $37.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Finally, Zacks Research downgraded Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Zai Lab currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

View Our Latest Analysis on ZLAB

Zai Lab Company Profile

(Get Free Report)

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.